RHHBY Roche Holdings AG ADR

Three ESMO Presidential trials, three survival wins vs standard of care 🧬 $RHHBY divarasib beat Lumakras/Krazati: OS HR 0.56 $SMMT partner Akeso's ivonescimab beat Imfinzi in bile duct cancer: OS HR 0.75 $AMGN Imdelltra + Imfinzi: OS HR 0.42 The catch in each, free:

36 days out on $RHHBY and it's quiet in a good way Nov 30 PDUFA, Priority Review, for giredestrant as adjuvant therapy in ER positive, HER2 negative stage I to III breast cancer. lidERA ran over 4100 patients and cut recurrence or death risk by 30 percent. At three years 92.4 percent had no invasive disease versus 89.6 percent on standard care. Closed Friday at 61.17, up 2.6 percent. imo the early read is the one that matters first

$RHHBY Moving in the right direction towards 65ps”Roche said it is fully prepared to launch its giredestrant breast-cancer pill later this year, pending authorization from U.S. regulators, and is nearing approval of its fenebrutinib tablet for multiple sclerosis.”